Product Description
Purchase the new Trasturel Trastuzumab 150 Mg Injection-a supreme, biotechnology-derived monoclonal antibody specifically designed for HER2-positive breast and gastric cancers. Marketed by the venerable Roche Products (India) Pvt Ltd, this anti-cancer injection features an exceptional lyophilized powder form that appears white to pale yellow. Utilise the offer for Trasturel, administered intravenously after reconstitution with sterile water. With a shelf life of 24 months, this prescription-only medication is contraindicated in cases of hypersensitivity. Dosage is tailored per physician's protocol, ensuring targeted excellence in adult care.
Type of Usage and Exceptional Advantages
Trasturel Trastuzumab 150 Mg Injection is tailored for intravenous infusion in adults diagnosed with HER2-positive metastatic breast or gastric cancer. Its supreme efficacy as a HER2 receptor antagonist delivers targeted therapy, maximizing clinical benefit while minimizing systemic toxicity. The revered Roche development ensures quality and reliability for healthcare professionals. Utilise this product's competitive advantages in precision oncology, applicable exclusively in prescription-based cancer treatments for superior patient outcomes.
FOB Port, Supply Ability, and Market Value
Dispatching from notable FOB ports across the domestic market, Trasturel Trastuzumab 150 Mg Injection offers significant supply ability tailored for importers, dealers, and distributors. Payment terms are adaptable to market demands, ensuring seamless transaction experiences for wholesalers and retailers. The product's prevailing market value is maintained through robust logistics, ensuring timely delivery within India's pharmaceutical network and extending global reach for international exporters and suppliers seeking reliability and supreme quality.
FAQ's of Trasturel Trastuzumab 150 Mg Injection:
Q: How should Trasturel Trastuzumab 150 Mg Injection be administered?
A: Trasturel is administered as an intravenous infusion. The lyophilized powder must be reconstituted and diluted with sterile water for injection according to the prescribing information, and dosage is decided by the treating physician.
Q: What are the key benefits of using Trasturel Trastuzumab for cancer patients?
A: Trasturel delivers targeted therapy for adults with HER2-overexpressing breast or gastric cancer, providing exceptional efficacy with a focus on reducing the growth of cancer cells while minimizing severe systemic side effects.
Q: When is Trasturel Trastuzumab indicated for use?
A: This medication is recommended for adults diagnosed with HER2-positive metastatic breast cancer or HER2-positive metastatic gastric cancer, as part of a physician-directed treatment protocol.
Q: Where should Trasturel Trastuzumab 150 Mg Injection be stored?
A: Trasturel should be stored at a controlled temperature between 2C and 8C. It must not be frozen and should be kept in its original packaging until reconstitution to maintain stability and effectiveness.
Q: What precautions should be considered before utilising Trasturel Trastuzumab?
A: The use of Trasturel is contraindicated in individuals with known hypersensitivity to Trastuzumab or its excipients. Possible adverse effects include infusion reactions, cardiotoxicity, fever, chills, nausea, and vomiting. Always consult a healthcare provider before beginning therapy.
Q: How is Trasturel supplied and packed for distribution?
A: Trasturel Trastuzumab comes as a single 150 mg vial of lyophilized powder, with one vial per box, making it suitable for dealers, distributors, wholesalers, and retailers involved in domestic or international pharmaceutical distribution.